Poorer outcomes seen with generic tacrolimus

08/15/2008 | Doctor's Guide

Patients treated with Tenacrine, a generic version of tacrolimus, after their first kidney transplant had a greater likelihood of rejecting the organ than did those treated with Prograf, the nongeneric version, according to the findings of a three-year study. About twice as many patients on the generic version developed acute rejection. Children younger than 10 years and with heart disease had a greater probability of rejecting the organ regardless of which drug they were given.

View Full Article in:

Doctor's Guide

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN